CTX.WAR Captor Therapeutics S.A.

Healthcare Biotechnology Warsaw Stock Exchange
53.70 PLN
Close of Oct 29, 2026
44.10 87.60
Market cap
PLN 348M
P/E
-
P/B
5.32x
ROE
-70.0%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CTX.WAR undervalued?

Graham number

The Graham number of Captor Therapeutics S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Captor Therapeutics S.A. fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-70.0%), below 10%.

ROA 0/1

Return on assets (-57.2%) is below the industry median (-18.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (7.7%) is above the industry median (2.6%).

Revenue Growth 0/2

Revenue shrank 20.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (4.1%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 1/2

Cash covers 1.4 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (5.5x) is above the industry median (3.6x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Captor Therapeutics S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Captor Therapeutics S.A.

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for…

Full company profile